

# Conference Program

**Tuesday, November 3**

---

- 1:00 p.m.-3:00 p.m. Plenary Session 1: Genomics**  
Imperial Ballroom AB  
*Session Chairperson: Jonathan A. Fletcher, Brigham and Women's Hospital, Boston, MA*
- 1:00 p.m. Identifying druggable mutations in pediatric solid tumors**  
Michael A. Dyer, St. Jude Children's Research Hospital, Memphis, TN
- 1:20 p.m. Novel monogenic and polygenic determinants of sarcoma risk: A clinic-based study of 1,162 families**  
David M. Thomas, Garvan Institute of Medical Research, Darlinghurst, Australia
- 1:40 p.m. Sarcoma genomics: Discovery and application**  
Elaine Mardis, Washington University, St. Louis, MO
- 2:00 p.m. Sarcoma functional genomics by human somatic cell mutagenesis**  
Rama Khokha, Princess Margaret Cancer Centre, Toronto, ON, Canada
- 2:20 p.m. Open discussion**
- 3:00 p.m.-3:30 p.m. Break**  
Imperial Ballroom Foyer
- 3:30 p.m.-5:00 p.m. Plenary Session 2: Metabolism**  
Imperial Ballroom AB  
*Session Chairperson: Robert G. Maki, Mount Sinai Medical Center, New York, NY*
- 3:30 p.m. Role of metabolism in cancer progression**  
Matthew G. Vander Heiden, Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, MA
- 3:50 p.m. Synovial sarcoma metabolomics landscape**  
Brian A. Van Tine, Washington University, St. Louis, MO
- 4:10 p.m. Genetic and epigenetic classification of SDH-deficient gastrointestinal stromal tumor**  
Paul S. Meltzer, National Cancer Institute, Bethesda, MD
- 4:30 p.m. Open discussion**
- 5:00 p.m.-7:00 p.m. Opening Reception**  
Imperial Ballroom CD

## Wednesday, November 4

---

- 7:00 a.m.-8:00 a.m. Continental Breakfast**  
Imperial Ballroom CD
- 8:00 a.m.-10:00 a.m. Plenary Session 3: Epigenetics and Transcription**  
Imperial Ballroom AB  
*Session Chairperson: Brian A. Van Tine, Washington University, St. Louis, MO*
- 8:00 a.m. Reversing misdirected chromatin remodeling in synovial sarcoma**  
Cigall Kadoch, Dana-Farber Cancer Institute, Boston, MA
- 8:20 a.m. Identifying epigenetic vulnerabilities in MPNST**  
Karen Cichowski, Brigham and Women's Hospital, Boston, MA
- 8:40 a.m. LSD Inhibitors in Ewing sarcoma**  
Stephen L. Lessnick, The Research Institute at Nationwide Children's Hospital, Columbus, OH
- 9:00 a.m. Zebrafish xenograft validation of combination EWS-FLI1 and MDM2/TP53 targeting**  
Pancras Hogendoorn, Leiden University Medical Centre, Leiden, The Netherlands
- 9:20 a.m. Open discussion**
- 10:00 a.m.-10:30 a.m. Break**  
Imperial Ballroom Foyer
- 10:30 a.m.-12:00 p.m. Plenary Session 4: Immunology**  
Imperial Ballroom AB  
*Session Chairperson: Angelo Paolo Dei Tos, General Hospital of Treviso, Treviso, Italy*
- 10:30 a.m. A brief history of sarcoma immunotherapy**  
Robert G. Maki, Mount Sinai Medical Center, New York, NY
- 10:50 a.m. Close interactions between dendritic cells and cancer**  
A. Karolina Palucka, The Jackson Laboratory for Genomic Medicine, Farmington, CT
- 11:10 a.m. Overcoming the sarcoma microenvironment for effective immunotherapy**  
Seth Pollack, University of Washington School of Medicine, Seattle, WA
- 11:30 a.m. Open discussion**
- 12:00 p.m.-2:00 p.m. Lunch on Own**

- 2:00 p.m.-3:30 p.m. Plenary Session 5: Novel Mechanisms: Myogenic Tumors**  
Imperial Ballroom AB  
*Session Chairperson: Lee J. Helman, National Cancer Institute, Bethesda, MD*
- 2:00 p.m. Notch signaling increases the number of relapse-driving tumor propagating cells in embryonal rhabdomyosarcoma**  
David M. Langenau, Massachusetts General Hospital/Harvard Medical School, Boston, MA
- 2:20 p.m. Dynamic cell-cycle dependent regulation of PAX3-FOXO1 tumorigenic function**  
Charles Keller, Oregon Health Science University, Portland, OR
- 2:40 p.m. Speaker to be announced**
- 3:00 p.m. Open discussion**
- 3:30 p.m. Closing Remarks**
- 5:00 p.m.- Start of CTOS Annual Meeting**